The latest secondary patent application, if granted, allows J&J to extend the monopoly on the drug used for treatment of drug resistant (DR-TB) till December 2027.
from Latest Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/iEQzOBg
https://ift.tt/O13Sn8y
from Latest Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/iEQzOBg
https://ift.tt/O13Sn8y
Post a Comment